Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (9642)	4/15/1999 11:58:00 AM
From: aknahow	Respond to of 17367

Financing roll into existing. Convertible at price of stock when conversion done. Can be redeamed for cash at XOMA's option. This means it is "floorless" but XOMA could if it had the cash by 2005 prevent issuance of more stock by just paying off the debt. Other indications exist for hu1124 but until they have got through the regulatory process on psoriasis they are not going to discuss them. Davis said there are several P II trials underway to determine doseage. Had been given once a week by I.V. Sub cutaneous is one of methods being looked at. Benefit persist after treatment stops, longer than standard treatment methods. Conference in Canada will provide the scientific data from previous trial. Well done call. Castello made sure question from in the room were repeated. They were otherwise inaudible. GNE person was there. Xoma meets with GNE several times a week. seemed like good relationship. Nothing else was covered but I have changed my mind and think the call was worth the effort. This is what I thought the presenters thought they said. It also on the "floorless" issue my own analysis of the meaning of what was said. Again Opala, thanks.